B. Khor, A. Gardet, and R. J. Xavier, Genetics and pathogenesis of inflammatory bowel disease, Nature, vol.474, pp.307-324, 2011.

P. Veiga, C. A. Gallini, C. Beal, M. Michaud, M. L. Delaney et al., Bifidobacterium animalis subsp. lactis fermented milk product reduces inflammation by altering a niche for colitogenic microbes, Proc Natl Acad Sci U S A, vol.107, pp.18132-18139, 2010.

N. P. Mcnulty, T. Yatsunenko, A. Hsiao, J. J. Faith, B. D. Muegge et al., The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins, Sci Transl Med, vol.3, pp.106-106, 2011.

L. G. Bermúdez-humarán, A. C. Motta, J. P. Deraison, C. Steidler, L. Vergnolle et al., Engineering lactococci and lactobacilli for human health, Curr Opin Microbiol, vol.16, issue.3, pp.278-83, 2013.

L. G. Bermudez-humaran, P. Kharrat, J. M. Chatel, and P. Langella, Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines, Microb Cell Fact, vol.10, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01189725

J. G. Leblanc, C. Aubry, C. Perez, N. G. , D. Moreno-de-leblanc et al., Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update, FEMS Microbiol Lett, vol.344, pp.1-9, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01019086

J. M. Wells and A. Mercenier, Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria, Nat Rev Microbiol, vol.6, pp.349-62, 2008.

L. Steidler, P. Rottiers, and B. Coulie, Actobiotics as a novel method for cytokine delivery, Ann N Y Acad Sci, vol.1182, pp.135-180, 2009.

L. Steidler and P. Rottiers, Therapeutic drug delivery by genetically modified Lactococcus lactis, Ann N Y Acad Sci, vol.1072, pp.176-86, 2006.

S. A. Limaye, R. I. Haddad, F. Cilli, S. T. Sonis, A. D. Colevas et al., Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy, Cancer, vol.119, pp.4268-76, 2013.

L. Steidler, W. Hans, L. Schotte, S. Neirynck, F. Obermeier et al., Treatment of murine colitis by Lactococcus lactis secreting interleukin-10, Science, vol.289, pp.1352-1357, 2000.

L. Steidler, S. Neirynck, N. Huyghebaert, V. Snoeck, A. Vermeire et al., Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10, Nat Biotechnol, vol.21, pp.785-794, 2003.

H. Braat, P. Rottiers, D. W. Hommes, N. Huyghebaert, E. Remaut et al., A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease, Clin Gastroenterol Hepatol, vol.4, pp.754-763, 2006.

J. P. Motta, L. Magne, D. Descamps, C. Rolland, C. Squarzoni-dale et al., Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis, Gastroenterology, vol.140, pp.1272-82, 2011.
URL : https://hal.archives-ouvertes.fr/pasteur-00552947

N. Cenac, C. N. Andrews, M. Holzhausen, K. Chapman, G. Cottrell et al., Role for protease activity in visceral pain in irritable bowel syndrome, J Clin Invest, vol.117, pp.636-683, 2007.

E. Hyun, P. Andrade-gordon, M. Steinhoff, and N. Vergnolle, Protease-activated receptor-2 activation: a major actor in intestinal inflammation, Gut, vol.57, pp.1222-1231, 2008.

J. P. Motta, L. G. Bermudez-humaran, C. Deraison, L. Martin, C. Rolland et al., Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis, Sci Transl Med, vol.4, pp.158-144, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01204261

Z. Z. Hamady, N. Scott, M. D. Farrar, M. Wadhwa, P. Dilger et al., Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF-beta1 under the control of dietary xylan 1, Inflamm Bowel Dis, vol.17, pp.1925-1960, 2011.

G. Monteleone, F. Pallone, and T. T. Macdonald, Smad7 in TGF-beta-mediated negative regulation of gut inflammation, Trends Immunol, vol.25, pp.513-520, 2004.

A. Miyoshi, I. Poquet, V. Azevedo, J. Commissaire, L. Bermudez-humaran et al., Controlled production of stable heterologous proteins in Lactococcus lactis, Appl Environ Microbiol, vol.68, pp.3141-3147, 2002.
URL : https://hal.archives-ouvertes.fr/hal-02683132

I. Poquet, V. Saint, E. Seznec, N. Simoes, A. Bolotin et al., HtrA is the unique surface housekeeping protease in Lactococcus lactis and is required for natural protein processing, Mol Microbiol, vol.35, pp.1042-51, 2000.
URL : https://hal.archives-ouvertes.fr/hal-02696130

C. Rigoulay, I. Poquet, S. M. Madsen, and A. Gruss, Expression of the Staphylococcus aureus surface proteins HtrA(1) and HtrA(2) in Lactococcus lactis, Fems Microbiol Lett, vol.237, pp.279-88, 2004.
URL : https://hal.archives-ouvertes.fr/hal-02682532

T. J. Gibson, , 1984.

M. J. Gasson, Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast-induced curing, J Bacteriol, vol.154, pp.1-9, 1983.

O. P. Kuipers, P. De-ruyter, M. Kleerebezem, and W. M. De-vos, Quorum sensingcontrolled gene expression in lactic acid bacteria, J Biotechnol, vol.64, pp.15-21, 1998.

P. A. Henriksen, M. Hitt, Z. Xing, J. Wang, C. Haslett et al., Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli, J Immunol, vol.172, pp.4535-4579, 2004.

L. G. Bermudez-humaran, P. Langella, J. Commissaire, S. Gilbert, L. Loir et al., Controlled intra-or extracellular production of staphylococcal nuclease and ovine omega interferon in Lactococcus lactis, FEMS Microbiol Lett, vol.224, pp.307-320, 2003.
URL : https://hal.archives-ouvertes.fr/hal-02679203

M. Vanasseldonk, G. Rutten, M. Oteman, R. J. Siezen, W. M. Devos et al., Cloning of Usp45, a gene encoding a secreted protein from lactococcuslactis subsp lactis Mg1363, Gene, vol.95, pp.155-60, 1990.

P. G. De-ruyter, O. P. Kuipers, and W. M. De-vos, Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin, Appl Environ Microbiol, vol.62, pp.3662-3669, 1996.

J. K. Triantafillidis, E. Merikas, and F. Georgopoulos, Current and emerging drugs for the treatment of inflammatory bowel disease, Drug Des Devel Ther, vol.5, pp.185-210, 2011.

K. W. Moore, M. R. De-waal, R. L. Coffman, O. Garra, and A. , Interleukin-10 and the interleukin-10 receptor, Annu Rev Immunol, vol.19, pp.683-765, 2001.

R. Kuhn, J. Lohler, D. Rennick, K. Rajewsky, and W. Muller, Interleukin-10-deficient mice develop chronic enterocolitis, Cell, vol.75, pp.263-74, 1993.

R. N. Fedorak, A. Gangl, C. O. Elson, P. Rutgeerts, S. Schreiber et al., Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The interleukin 10 inflammatory bowel disease cooperative study group, Gastroenterology, vol.119, pp.1473-82, 2000.

J. O. Lindsay, C. J. Ciesielski, T. Scheinin, H. J. Hodgson, and F. M. Brennan, The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding IL-10, J Immunol, vol.166, pp.7625-7658, 2001.

J. Lindsay, C. Van-montfrans, F. Brennan, S. Van-deventer, P. Drillenburg et al., IL-10 gene therapy prevents TNBS-induced colitis, Gene Ther, vol.9, pp.1715-1736, 2002.

G. Barbara, Z. Xing, C. M. Hogaboam, J. Gauldie, and S. M. Collins, Interleukin 10 gene transfer prevents experimental colitis in rats, Gut, vol.46, pp.344-353, 2000.

J. O. Lindsay, C. J. Ciesielski, T. Scheinin, F. M. Brennan, and H. J. Hodgson, Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis, Gut, vol.52, pp.981-988, 2003.

H. Groux, A. O'garra, M. Bigler, M. Rouleau, S. Antonenko et al., A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis, Nature, vol.389, pp.737-779, 1997.

P. L. Beck, I. M. Rosenberg, R. J. Xavier, T. Koh, J. F. Wong et al., Transforming growth factor-beta mediates intestinal healing and susceptibility to injury in vitro and in vivo through epithelial cells, Am J Pathol, vol.162, pp.597-608, 2003.

J. K. Roche, C. A. Martins, R. Cosme, R. Fayer, and R. L. Guerrant, Transforming growth factor beta1 ameliorates intestinal epithelial barrier disruption by Cryptosporidium parvum in vitro in the absence of mucosal T lymphocytes, Infect Immun, vol.68, pp.5635-5679, 2000.

K. L. Howe, C. Reardon, A. Wang, A. Nazli, and D. M. Mckay, Transforming growth factor-beta regulation of epithelial tight junction proteins enhances barrier function and blocks enterohemorrhagic Escherichia coli O157:H7-induced increased permeability, Am J Pathol, vol.167, pp.1587-97, 2005.

T. Moreau, K. Baranger, S. Dade, S. Dallet-choisy, N. Guyot et al., Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family, Biochimie, vol.90, pp.284-95, 2008.

J. M. Sallenave and A. Silva, Characterization and gene sequence of the precursor of elafin, an elastase-specific inhibitor in bronchial secretions, Am J Respir Cell Mol Biol, vol.8, pp.439-484, 1993.

M. W. Butler, I. Robertson, C. M. Greene, S. J. O'neill, C. C. Taggart et al., Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway, J Biol Chem, vol.281, pp.34730-34735, 2006.

L. Watterlot, M. Meyrand, N. Gaide, P. Kharrat, S. Blugeon et al., Variations of N-acetylation level of peptidoglycan do not influence persistence of Lactococcus lactis in the gastrointestinal tract, Int J Food Microbiol, vol.144, pp.29-34, 2010.

, Submit your next manuscript to BioMed Central and take full advantage of: ? Convenient online submission ? Thorough peer review ? No space constraints or color figure charges ? Immediate publication on acceptance ? Inclusion in PubMed, CAS, Scopus and Google Scholar ? Research which is freely available for redistribution Submit your manuscript at www